BioArk - Investor Profile and Portfolio

ExcellGene’s service offer covers the value chain from a DNA vector to a purified protein made by CHO or any other animal cells in bioreactors, ranging from milliliters to the multi-hundred-liter scale of operation. It offers services for protein production; generation and optimization of stable mammalian cell-lines; Process Development and Scale-Up; protein recovery and analysis; and Consulting services. The company's technologies of transient and stable gene expression and scalable disposable cultivation systems support its clients’ from early discovery, pre-clinical testing through to clinical testing and to manufacturing.

Karmagenes is developing a genetic test that provides insights about individual's personality and behavior. Helps user to understand the significance of DNA on changing their personality along with environment factors and upbringing. Targeted market includes individuals, families, dating sites and social networks, and personality test providers. Also provides counseling service with genetic experts.

Inflamalps is a Swiss biopharmaceutical company developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology. They focus on Dry Eye and Sjögren syndrome, Uveitis and Atopic dermatitis. Their lead candidate INF101 , for dry eye and uvetis is currently in pre-clinical phase. INF01 functions by inhibiting the production of a cytokine involved in dry eye syndrome. INF101 was in-licensed from Onconox for development in ophthalmological indications

CEIDOS is a provider of cell culturing devices for patients' cell modification. The device helps in the manufacturing of drugs for various diseases like cell diseases, cancer, and many more.